IKENA ONCOLOGY INC (IKNA)

Company Profile

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed, and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 57 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company’s lead targeted oncology program, IK-930, is a TEAD1 selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company’s additional research spans other targets in the Hippo pathway, as well as the RAS signaling pathway, including developing IK-595, a novel MEK-RAF inhibitor. Additionally, IK-175, an aryl hydrocarbon receptor (AHR) antagonist, is being developed in collaboration with Bristol Myers Squibb. The company also offers clinical programs, including PY314 and PY159, targeting TREM2 and TREM1 respectively, and are designed to selectively deplete and in some cases reprogram certain tumor-associated macrophages responsible for immunosuppression.

Company Info

IKENA ONCOLOGY INC

50 Northern Ave.

Boston MASSACHUSETTS 02210

P: 18573438292

CEO: Mark Manfredi

Employees: 57

Website: https://www.ikenaoncology.com